Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Urticarial vasculitis

Identifieur interne : 002173 ( Main/Exploration ); précédent : 002172; suivant : 002174

Urticarial vasculitis

Auteurs : Joe Venzor [États-Unis] ; Wai L. Lee [États-Unis] ; David P. Huston [États-Unis]

Source :

RBID : ISTEX:5572D4CFAEB04E1A5506C64BE4EECFE7AB33B8A9

English descriptors

Abstract

Abstract: Urticarial vasculitis is a clinico-pathologic entity typified by recurrent episodes of urticaria that have the histopathologic features of leukocytoclastic vasculitis. The cutaneous features may include painful, burning or pruritic skin lesions, the persistence of individual lesions greater than 24 hours, palpable purpura, pronounced central clearing of lesions, and residual hyperpigmentation following resolution. However, because clinical characteristics of urticarial vasculitis may overlap with those of allergic urticaria, confirmation of the diagnosis requires a lesional skin biopsy. This condition is idiopathic in many patients but can also occur in the context of autoimmune disorders, infections, drug reactions, or as a paraneoplastic syndrome. In idiopathic urticarial vasculitis common laboratory findings are an elevation of erythrocyte sedimentation rate and reduction of serum complement. An association between urticarial vasculitis and systemic lupus erythematosus has been hypothesized as some clinical manifestations of disease overlap and C1q autoantibodies may be present in both diseases. Normo-complementemic patients usually have minimal or no systemic involvement and often have a better prognosis. On-the-other-hand, hypocomplementemic patients have the propensity to have more severe multi-organ involvement. Response to treatment is variable and a wide variety of therapeutic agents may be efficacious. Initial recommendations for treatment of urticarial vasculitis manifest only as non-necrotizing skin lesions include antihistamines, dapsone, colchicine, hydroxychloroquine or indomethacin, but corticosteroids are often required. With necrotizing skin lesions or visceral involvement, corticosteroids are regularly indicated. Cases of severe corticosteroid resistant urticarial vasculitis or where corticosteroid morbidity is evident may require treatment with other immunosuppressive agents such as azathioprine, cyclophosphamide, or cyclosporine.

Url:
DOI: 10.1385/CRIAI:23:2:201


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Urticarial vasculitis</title>
<author>
<name sortKey="Venzor, Joe" sort="Venzor, Joe" uniqKey="Venzor J" first="Joe" last="Venzor">Joe Venzor</name>
</author>
<author>
<name sortKey="Lee, Wai L" sort="Lee, Wai L" uniqKey="Lee W" first="Wai L." last="Lee">Wai L. Lee</name>
</author>
<author>
<name sortKey="Huston, David P" sort="Huston, David P" uniqKey="Huston D" first="David P." last="Huston">David P. Huston</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5572D4CFAEB04E1A5506C64BE4EECFE7AB33B8A9</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1385/CRIAI:23:2:201</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-G5WSMJP6-R/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000454</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000454</idno>
<idno type="wicri:Area/Istex/Curation">000454</idno>
<idno type="wicri:Area/Istex/Checkpoint">001000</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001000</idno>
<idno type="wicri:Area/Main/Merge">002195</idno>
<idno type="wicri:Area/Main/Curation">002173</idno>
<idno type="wicri:Area/Main/Exploration">002173</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Urticarial vasculitis</title>
<author>
<name sortKey="Venzor, Joe" sort="Venzor, Joe" uniqKey="Venzor J" first="Joe" last="Venzor">Joe Venzor</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>10470 Vista del Sol, Suite 100, 79925, El Paso</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Lee, Wai L" sort="Lee, Wai L" uniqKey="Lee W" first="Wai L." last="Lee">Wai L. Lee</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>Immunology Allergy and Rheumatology Section, Department of Medicine, Baylor College of Medicine, 77030, Houston</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Huston, David P" sort="Huston, David P" uniqKey="Huston D" first="David P." last="Huston">David P. Huston</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Medicine, Baylor College of Medicine, 77030, Houston</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Immunology, Biology of Inflammation Center; Immunology Allergy and Rheumatology Section, Baylor College of Medicine, 77030, Houston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Clinical Reviews in Allergy & Immunology</title>
<title level="j" type="abbrev">Clinic Rev Allerg Immunol</title>
<idno type="ISSN">1080-0549</idno>
<idno type="eISSN">1559-0267</idno>
<imprint>
<publisher>Humana Press</publisher>
<pubPlace>Totowa</pubPlace>
<date type="published" when="2002-10-01">2002-10-01</date>
<biblScope unit="volume">23</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="201">201</biblScope>
<biblScope unit="page" to="216">216</biblScope>
</imprint>
<idno type="ISSN">1080-0549</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1080-0549</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Urticarial vasculitis</term>
<term>anti-C1q autoantibodies</term>
<term>chronic urticaria</term>
<term>hypocomplementemia</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Urticarial vasculitis is a clinico-pathologic entity typified by recurrent episodes of urticaria that have the histopathologic features of leukocytoclastic vasculitis. The cutaneous features may include painful, burning or pruritic skin lesions, the persistence of individual lesions greater than 24 hours, palpable purpura, pronounced central clearing of lesions, and residual hyperpigmentation following resolution. However, because clinical characteristics of urticarial vasculitis may overlap with those of allergic urticaria, confirmation of the diagnosis requires a lesional skin biopsy. This condition is idiopathic in many patients but can also occur in the context of autoimmune disorders, infections, drug reactions, or as a paraneoplastic syndrome. In idiopathic urticarial vasculitis common laboratory findings are an elevation of erythrocyte sedimentation rate and reduction of serum complement. An association between urticarial vasculitis and systemic lupus erythematosus has been hypothesized as some clinical manifestations of disease overlap and C1q autoantibodies may be present in both diseases. Normo-complementemic patients usually have minimal or no systemic involvement and often have a better prognosis. On-the-other-hand, hypocomplementemic patients have the propensity to have more severe multi-organ involvement. Response to treatment is variable and a wide variety of therapeutic agents may be efficacious. Initial recommendations for treatment of urticarial vasculitis manifest only as non-necrotizing skin lesions include antihistamines, dapsone, colchicine, hydroxychloroquine or indomethacin, but corticosteroids are often required. With necrotizing skin lesions or visceral involvement, corticosteroids are regularly indicated. Cases of severe corticosteroid resistant urticarial vasculitis or where corticosteroid morbidity is evident may require treatment with other immunosuppressive agents such as azathioprine, cyclophosphamide, or cyclosporine.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Texas</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Texas">
<name sortKey="Venzor, Joe" sort="Venzor, Joe" uniqKey="Venzor J" first="Joe" last="Venzor">Joe Venzor</name>
</region>
<name sortKey="Huston, David P" sort="Huston, David P" uniqKey="Huston D" first="David P." last="Huston">David P. Huston</name>
<name sortKey="Huston, David P" sort="Huston, David P" uniqKey="Huston D" first="David P." last="Huston">David P. Huston</name>
<name sortKey="Lee, Wai L" sort="Lee, Wai L" uniqKey="Lee W" first="Wai L." last="Lee">Wai L. Lee</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002173 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002173 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:5572D4CFAEB04E1A5506C64BE4EECFE7AB33B8A9
   |texte=   Urticarial vasculitis
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021